We have an updated report [Version - 2025] available. Kindly sign up to get the sample of the report.

IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In: 26 Aug, 2022
Code: CMI2560
Pages: 238
Formats: Excel and PDF
Industry: Biotechnology

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)

Key features of the study:

This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immune checkpoint inhibitors market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market

Detailed Segmentation:

Global Immune Checkpoint Inhibitors Market, By Drug Class:
- Programmed Death Receptor-1 (PD-1) Inhibitors
  - Pembrolizumab (Keytruda)
  - Nivolumab (Opdivo)
  - Cemiplimab (Libtayo)
  - Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
  - Atezolizumab (Tecentriq)
  - Avelumab (Bavencio)
  - Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
  - Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
Global Immune Checkpoint Inhibitors Market, By Cancer Type:
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Blood Cancer (Lymphoma)
- Bladder Cancer (Urothelial Carcinoma)
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Immune Checkpoint Inhibitors Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Region
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Bristol-Myers Squibb Company*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- AstraZeneca Plc
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

Global Immune Checkpoint Inhibitors Market, By Drug Class:
- Programmed Death Receptor-1 (PD-1) Inhibitors
  - Pembrolizumab (Keytruda)
  - Nivolumab (Opdivo)
  - Cemiplimab (Libtayo)
  - Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
  - Atezolizumab (Tecentriq)
  - Avelumab (Bavencio)
  - Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
  - Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
Global Immune Checkpoint Inhibitors Market, By Cancer Type:
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Blood Cancer (Lymphoma)
- Bladder Cancer (Urothelial Carcinoma)
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Immune Checkpoint Inhibitors Market, By Region:
- North America
  - By Drug Class
    - Programmed Death Receptor-1 (PD-1) Inhibitors
      - Pembrolizumab (Keytruda)
      - Nivolumab (Opdivo)
      - Cemiplimab (Libtayo)
      - Others
    - Programmed Death-Ligand 1 (PD-L1) Inhibitors
      - Atezolizumab (Tecentriq)
      - Avelumab (Bavencio)
      - Durvalumab (Imfinzi)
    - CTL-4 Checkpoint Inhibitor
      - Ipilimumab (Yervoy)
    - Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    - Lymphocyte-Activation Gene 3 Inhibitors
  - By Cancer Type:
    - Lung Cancer
    - Head & Neck Cancer
    - Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    - Blood Cancer (Lymphoma)
    - Bladder Cancer (Urothelial Carcinoma)
    - Renal/Kidney Cancer
    - Colorectal Cancer
    - Breast Cancer
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Drug Class
    - Programmed Death Receptor-1 (PD-1) Inhibitors
      - Pembrolizumab (Keytruda)
      - Nivolumab (Opdivo)
      - Cemiplimab (Libtayo)
      - Others
    - Programmed Death-Ligand 1 (PD-L1) Inhibitors
      - Atezolizumab (Tecentriq)
      - Avelumab (Bavencio)
      - Durvalumab (Imfinzi)
    - CTL-4 Checkpoint Inhibitor
      - Ipilimumab (Yervoy)
    - Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    - Lymphocyte-Activation Gene 3 Inhibitors
  - By Cancer Type:
    - Lung Cancer
    - Head & Neck Cancer
    - Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    - Blood Cancer (Lymphoma)
    - Bladder Cancer (Urothelial Carcinoma)
    - Renal/Kidney Cancer
    - Colorectal Cancer
    - Breast Cancer
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Drug Class
    - Programmed Death Receptor-1 (PD-1) Inhibitors
      - Pembrolizumab (Keytruda)
      - Nivolumab (Opdivo)
      - Cemiplimab (Libtayo)
      - Others
    - Programmed Death-Ligand 1 (PD-L1) Inhibitors
      - Atezolizumab (Tecentriq)
      - Avelumab (Bavencio)
      - Durvalumab (Imfinzi)
    - CTL-4 Checkpoint Inhibitor
      - Ipilimumab (Yervoy)
    - Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    - Lymphocyte-Activation Gene 3 Inhibitors
  - By Cancer Type:
    - Lung Cancer
    - Head & Neck Cancer
    - Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    - Blood Cancer (Lymphoma)
    - Bladder Cancer (Urothelial Carcinoma)
    - Renal/Kidney Cancer
    - Colorectal Cancer
    - Breast Cancer
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Drug Class
    - Programmed Death Receptor-1 (PD-1) Inhibitors
      - Pembrolizumab (Keytruda)
      - Nivolumab (Opdivo)
      - Cemiplimab (Libtayo)
      - Others
    - Programmed Death-Ligand 1 (PD-L1) Inhibitors
      - Atezolizumab (Tecentriq)
      - Avelumab (Bavencio)
      - Durvalumab (Imfinzi)
    - CTL-4 Checkpoint Inhibitor
      - Ipilimumab (Yervoy)
    - Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    - Lymphocyte-Activation Gene 3 Inhibitors
  - By Cancer Type:
    - Lung Cancer
    - Head & Neck Cancer
    - Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    - Blood Cancer (Lymphoma)
    - Bladder Cancer (Urothelial Carcinoma)
    - Renal/Kidney Cancer
    - Colorectal Cancer
    - Breast Cancer
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Drug Class
    - Programmed Death Receptor-1 (PD-1) Inhibitors
      - Pembrolizumab (Keytruda)
      - Nivolumab (Opdivo)
      - Cemiplimab (Libtayo)
      - Others
    - Programmed Death-Ligand 1 (PD-L1) Inhibitors
      - Atezolizumab (Tecentriq)
      - Avelumab (Bavencio)
      - Durvalumab (Imfinzi)
    - CTL-4 Checkpoint Inhibitor
      - Ipilimumab (Yervoy)
    - Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    - Lymphocyte-Activation Gene 3 Inhibitors
  - By Cancer Type:
    - Lung Cancer
    - Head & Neck Cancer
    - Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    - Blood Cancer (Lymphoma)
    - Bladder Cancer (Urothelial Carcinoma)
    - Renal/Kidney Cancer
    - Colorectal Cancer
    - Breast Cancer
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Drug Class
    - Programmed Death Receptor-1 (PD-1) Inhibitors
      - Pembrolizumab (Keytruda)
      - Nivolumab (Opdivo)
      - Cemiplimab (Libtayo)
      - Others
    - Programmed Death-Ligand 1 (PD-L1) Inhibitors
      - Atezolizumab (Tecentriq)
      - Avelumab (Bavencio)
      - Durvalumab (Imfinzi)
    - CTL-4 Checkpoint Inhibitor
      - Ipilimumab (Yervoy)
    - Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    - Lymphocyte-Activation Gene 3 Inhibitors
  - By Cancer Type:
    - Lung Cancer
    - Head & Neck Cancer
    - Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    - Blood Cancer (Lymphoma)
    - Bladder Cancer (Urothelial Carcinoma)
    - Renal/Kidney Cancer
    - Colorectal Cancer
    - Breast Cancer
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Region
    - South Africa
    - Central Africa
    - North Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

IMMUNE CHECKPOINT INHIBITORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Detailed Segmentation:

Global Immune Checkpoint Inhibitors Market, By Drug Class:

Global Immune Checkpoint Inhibitors Market, By Cancer Type:

Global Immune Checkpoint Inhibitors Market, By Distribution Channel:

Global Immune Checkpoint Inhibitors Market, By Region:

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :